SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Salim A)
 

Sökning: WFRF:(Salim A) > (2005-2009) > Effects of fondapar...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003781naa a2200493 4500
001oai:DiVA.org:uu-14694
003SwePub
008080131s2008 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-146942 URI
0247 a https://doi.org/10.1093/eurheartj/ehm5782 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Oldgren, Jonas,d 1964-u Uppsala universitet,Institutionen för medicinska vetenskaper,UCR4 aut0 (Swepub:uu)jonaoldg
2451 0a Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment
264 c 2008-01-17
264 1b Oxford University Press (OUP),c 2008
338 a print2 rdacarrier
520 a AIMS: At least one quarter of ST-segment elevation myocardial infarction (STEMI) patients do not receive reperfusion therapy, and these patients are at high risk for new ischaemic events. We evaluated fondaparinux treatment vs. usual care, i.e. placebo or unfractionated (UF) heparin, in a pre-specified subgroup of 2867 (out of 12 092) patients not receiving reperfusion treatment in the OASIS-6 trial. METHODS: In all, 1458 patients were randomized to fondaparinux 2.5 mg once daily subcutaneously up to 8 days and 1409 patients to usual care (control). Randomization was stratified by indication for UF heparin (stratum II, n = 1226) or not (stratum I, n = 1641) based on the investigator's judgment. RESULTS: The proportion of patients who suffered death or myocardial re-infarction at 30 days (primary outcome) was 12.2% in the fondaparinux vs. 15.1% in the control group, hazard ratio (HR) 0.80; 95% confidence interval (CI) 0.65-0.98. There was no increase in severe bleedings, HR 0.82; CI 0.44-1.55, or strokes, HR 0.62; CI 0.29-1.33. Consequently, the composite of death, myocardial re-infarction, or severe bleeding were significantly reduced at 30 days, HR 0.81; CI 0.67-0.99. Reductions in death or myocardial re-infarction at 30 days were consistent in stratum I with fondaparinux vs. placebo, HR 0.88; 95% CI 0.65-1.19, and in stratum II with fondaparinux vs. UF heparin infusion for 24-48 h (n = 806), HR 0.74; CI 95% 0.57-0.97, P = 0.41 for heterogeneity. CONCLUSION: In STEMI patients not receiving reperfusion treatment, fondaparinux reduces the composite of death or myocardial re-infarction without an increase in severe bleedings or strokes as compared to placebo or UF heparin.
653 a Acute myocardial infarction
653 a Anticoagulants
653 a MEDICINE
653 a MEDICIN
7001 a Wallentin, Lars,d 1943-u Uppsala universitet,Institutionen för medicinska vetenskaper,UCR4 aut0 (Swepub:uu)larswall
7001 a Afzal, Rizwan4 aut
7001 a Bassand, Jean-Pierre4 aut
7001 a Budaj, Andrzej4 aut
7001 a Chrolavicius, Susan4 aut
7001 a Fox, Keith A. A.4 aut
7001 a Granger, Christopher B.4 aut
7001 a Mehta, Shamir R.4 aut
7001 a Pais, Prem4 aut
7001 a Peters, Ron J. G.4 aut
7001 a Xavier, Denis4 aut
7001 a Zhu, Jun4 aut
7001 a Yusuf, Salim4 aut
7102 a Uppsala universitetb Institutionen för medicinska vetenskaper4 org
7730 t European Heart Journald : Oxford University Press (OUP)g 29:3, s. 315-23q 29:3<315-23x 0195-668Xx 1522-9645
8564 u http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=18084015&dopt=Citation
8564 u https://academic.oup.com/eurheartj/article-pdf/29/3/315/1365866/ehm578.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-14694
8564 8u https://doi.org/10.1093/eurheartj/ehm578

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy